Overview
CTNM market data
Price History
CTNM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 45.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.23 – $16.91 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $545.1M · P/B 1.60.
Company News
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23Benzinga · Jul 31, 2026, 6:43 PM
Contineum Therapeutics shares are trading lower after the company reported its Q2 financial results. The company announced a workforce reduction.Benzinga · Jul 31, 2026, 3:16 PM
Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel LorrainBenzinga · Jul 30, 2026, 9:16 PM
Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) EstimateBenzinga · Jul 30, 2026, 8:21 PM
8-K filing — Contineum Therapeutics, Inc. (CTNM)SEC EDGAR · Jul 30, 2026, 8:08 PM
Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medicinal ChemistryBenzinga · Jun 30, 2026, 8:10 PM
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16Benzinga · May 14, 2026, 4:45 PM